The manufacturer identified for Ibruxen 140 mg is Everest Pharmaceuticals Ltd. Everest’s product database lists Ibruxen as Ibrutinib INN 140 mg.
Manufacturer and product relationship
| Role | Entity |
|---|---|
| Ibruxen manufacturer | Everest Pharmaceuticals Ltd. |
| Ibruxen active ingredient | Ibrutinib |
| Ibruxen strength | 140 mg |
| Ibruxen dosage form | Capsule |
| Reference brand | IMBRUVICA |
| Reference-product development | Pharmacyclics/Janssen collaboration |
Who developed ibrutinib?
The development history of ibrutinib is associated with Pharmacyclics and Janssen. Janssen described IMBRUVICA as jointly developed and commercialized by Janssen and Pharmacyclics.
Pharmacyclics later became an AbbVie company, while Janssen continued its collaboration and commercialization role.
Manufacturer versus originator
These roles should not be confused.
A manufacturer makes a specific pharmaceutical product.
An originator/developer is associated with the development of the active pharmaceutical ingredient and/or original reference medicine.
A brand owner owns a particular commercial brand.
A marketing authorization holder is legally responsible for a medicinal product authorization in a particular jurisdiction.
A distributor handles supply and distribution.
These roles can belong to different organizations.
Quality information
Specific manufacturing-site, batch-release, GMP-certification or authorization details should be verified against current Everest Pharmaceuticals documentation and applicable regulatory records rather than assumed from the existence of the product.